Applying synthetic biology to probiotics to develop novel living medicines
Synlogic is developing a novel class of living Synthetic Biotic medicines based on its proprietary drug development platform. The company’s initial pipeline includes potential first-in-class treatments for orphan genetic diseases such as urea cycle disorders (UCD) and phenylketonuria (PKU). In addition, the company intends to leverage the potential of its platform to create additional potential first-in-class therapies for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer.
